Drugs / LErafAON-ETU
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00100672 | Dec 2004 → Oct 2009 | neoplasm | INSYS Therapeutics Inc | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LErafAON-ETU | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00100672 ↗ |
| Action | Inhibit | “LErafAON-ETU potentially limits the ability of a cell to produce the Raf-1 protein.” NCT00100672 ↗ |
| Modality | Antisense oligonucleotide | “antisense oligonucleotides specific to c-raf” NCT00100672 ↗ |
| Route | Intravenous | “Patients will receive an intravenous infusion of LErafAON-ETU each week.” NCT00100672 ↗ |
| Target | RAF1 | “antisense oligonucleotides specific to c-raf” NCT00100672 ↗ |